Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uterine fibroids.

E A Stewart1

  • 1Center for Uterine Fibroids, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA. eastewart@partners.org

Lancet (London, England)
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Premature or early bilateral oophorectomy: a 2021 update.

Climacteric : the journal of the International Menopause Society·2021
Same author

What do we do when new fibroids form following myomectomy?

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.

Human reproduction open·2019
Same author

Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.

Human reproduction (Oxford, England)·2019
Same author

Academic advocacy in public health: Disciplinary 'duty' or political 'propaganda'?

Social science & medicine (1982)·2017
Same author

Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners.

Journal of viral hepatitis·2017
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Uterine leiomyomas (fibroids) are common benign uterine tumors causing significant morbidity. New research into fibroid biology and targeted therapies may offer better future treatment options beyond surgery and hormone manipulation.

Area of Science:

  • Gynecologic Oncology
  • Reproductive Endocrinology
  • Tumor Biology

Background:

  • Uterine leiomyomas (fibroids) are the most frequent reason for hysterectomy in women.
  • Fibroids affect up to 25% of women, causing heavy bleeding, pain, and reproductive issues, impacting quality of life and incurring substantial economic costs.
  • Current treatments like surgery and hormone therapy have limitations, including recurrence and side effects.

Purpose of the Study:

  • To review the current understanding of uterine leiomyoma biology and treatment options.
  • To highlight the need for evidence-based evaluation of fibroid therapies.
  • To explore potential future treatments based on molecular and genetic insights.

Main Methods:

  • Review of existing literature on uterine leiomyomas, their clinical presentation, and treatment modalities.

Related Experiment Videos

  • Analysis of current therapeutic strategies, including surgical interventions and hormonal treatments.
  • Discussion of emerging research into the biological mechanisms underlying fibroid development.

    • Main Results:

    • Surgery remains the primary treatment, but recurrence is a significant issue.
    • Hormonal therapies are effective but limited by side effects, necessitating exploration of hormone antagonists.
    • Understanding the role of growth factors and genetic mutations is crucial for developing novel therapies.

    Conclusions:

    • There is a need for more evidence-based evaluation of uterine leiomyoma treatments.
    • Targeting the steroid-hormone environment with specific antagonists shows promise.
    • Future advancements in understanding fibroid biology may lead to innovative therapeutic approaches.